Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Oncopeptides AB ( (SE:ONCO) ) just unveiled an update.
Oncopeptides AB announced that a panel of multiple myeloma experts has endorsed the use of its drug Pepaxti, also known as melflufen, for treating relapsed, refractory multiple myeloma. The expert consensus, published in the Annals of Hematology, emphasizes Pepaxti’s effectiveness for heavily pretreated patients, including the elderly and those with high-risk disease profiles, reinforcing its role as a critical treatment option. This endorsement strengthens Pepaxti’s market positioning and confirms its utility across diverse patient subgroups, aligning with findings from pivotal studies and real-world applications.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.00 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
More about Oncopeptides AB
Oncopeptides is a Swedish biotechnology company specializing in the development and commercialization of targeted therapies for challenging cancer types. Utilizing its proprietary Peptide Drug Conjugate platform, the company creates compounds that deliver cytotoxic agents directly into cancer cells. Oncopeptides’ flagship drug, Pepaxti, is being marketed in Europe and has partnerships in South Korea, the Middle East, and Africa. Founded in 2000, the company operates in several European countries and is listed on Nasdaq Stockholm.
Average Trading Volume: 3,641,289
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.26B
See more data about ONCO stock on TipRanks’ Stock Analysis page.